Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects

Silai YU; Jianjiao NI; Zhengfei ZHU

doi:10.19401/j.cnki.1007-3639.2022.06.003

您当前的位置：

首页 >

文章列表页 >

Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects

Specialists' Commentary | 更新时间：2025-12-31

- Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects
- China Oncology Vol. 32, Issue 6, Pages: 487-498(2022)
- 作者机构：
  
  1. 复旦大学上海医学院基础医学院,上海 200032
  2. 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系,上海 200032
  3. 复旦大学胸部肿瘤研究所,上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.06.003
  CLC： R734.2
- Received：15 April 2022，
  
  Revised：2022-05-16，
  
  Published：30 June 2022
- 稿件说明：
移动端阅览
Silai YU, Jianjiao NI, Zhengfei ZHU. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects[J]. China Oncology, 2022, 32(6): 487-498.
DOI：

Silai YU, Jianjiao NI, Zhengfei ZHU. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects[J]. China Oncology, 2022, 32(6): 487-498. DOI： 10.19401/j.cnki.1007-3639.2022.06.003.

摘要

PACIFIC研究拉开了不可手术局部晚期非小细胞肺癌（locally advanced non-small cell lung cancer

LA-NSCLC）免疫治疗新时代的序幕

同时也提出了如何将放化疗与免疫治疗有机整合及进一步优化的新命题。本文对不可手术LA-NSCLC的治疗进展进行综述

旨在探讨免疫治疗背景下LA-NSCLC的研究现况和未来方向。本文将汇总PACIFIC研究的更新数据和这个模式在特殊人群

如老年、程序性死亡[蛋白

]

配体-1（programmed death ligand-1

PD-L1）阴性、表皮生长因子受体（epidermal growth factor receptor

EGFR

）基因突变的研究进展

探讨放化疗和免疫治疗的最佳时序安排。回顾放疗在剂量分割、靶区勾画、射线选择方面的技术进步和实施优化的探索

并展望其在免疫治疗时代的应用前景。

Abstract

The PACIFIC trial uncovered a new era of immunotherapy in the multi-disciplinary treatment of unresectable locally advanced non-small cell lung cancer (LA-NSCLC)

but also proposed a new question of how to further optimize radiotherapy and chemotherapy

in order to maximize synergistic effects with immunotherapy. The treatment progress of unresectable LA-NSCLC was reviewed in the context of immunotherapy. Updated data of the PACIFIC trial along with the research progress among special populations

especially for elderly patients

programmed death ligand-1 (PD-L1) expression negative and epidermal growth factor receptor (EGFR) gene mutant were summarized. Meanwhile

the optimal sequence of radiotherapy

chemotherapy and immunotherapy

the technical advancement and implementation of radiotherapy

including dose fractionation

target delineation and ray selection

were discussed

as well as its application prospect in the era of immunotherapy.

关键词

Keywords

references

ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

EBERHARDT W E E , DE RUYSSCHER D , WEDER W , et al . 2nd ESMO consensus conference in lung cancer: locally advanced stage Ⅲ non-small cell lung cancer [J ] . Ann Oncol , 2015 , 26 ( 8 ): 1573 - 1588 . DOI: 10.1093/annonc/mdv187 http://doi.org/10.1093/annonc/mdv187 https://linkinghub.elsevier.com/retrieve/pii/S0923753419318411 https://linkinghub.elsevier.com/retrieve/pii/S0923753419318411

ANTONIA S J , VILLEGAS A , DANIEL D , et al . Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer [J ] . N Engl J Med , 2017 , 377 ( 20 ): 1919 - 1929 . DOI: 10.1056/NEJMoa1709937 http://doi.org/10.1056/NEJMoa1709937 http://www.nejm.org/doi/10.1056/NEJMoa1709937 http://www.nejm.org/doi/10.1056/NEJMoa1709937

BANG A , SCHOENFELD J D , SUN A Y . PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer [J ] . Transl Lung Cancer Res , 2019 , 8 ( Suppl 2 ): S139-S146.

FAIVRE-FINN C , VICENTE D , KURATA T , et al . Four-year survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC-an update from the PACIFIC trial [J ] . J Thorac Oncol , 2021 , 16 ( 5 ): 860 - 867 . DOI: 10.1016/j.jtho.2020.12.015 http://doi.org/10.1016/j.jtho.2020.12.015 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000228 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000228

SPIGEL D R , FAIVRE-FINN C , GRAY J E , et al . Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer [J ] . J Clin Oncol , 2022 , 40 ( 12 ): 1301 - 1311 . DOI: 10.1200/JCO.21.01308 http://doi.org/10.1200/JCO.21.01308 https://ascopubs.org/doi/10.1200/JCO.21.01308 https://ascopubs.org/doi/10.1200/JCO.21.01308

NAIDOO J , VANSTEENKISTE J F , FAIVRE-FINN C , et al . Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage Ⅲ NSCLC: a post-hoc analysis of the PACIFIC trial [J ] . Lung Cancer , 2022 , 166 : 84 - 93 . DOI: 10.1016/j.lungcan.2022.02.003 http://doi.org/10.1016/j.lungcan.2022.02.003 https://linkinghub.elsevier.com/retrieve/pii/S0169500222000435 https://linkinghub.elsevier.com/retrieve/pii/S0169500222000435

PANJE C M , LUPATSCH J E , BARBIER M , et al . A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage Ⅲ NSCLC responding to definitive radiochemotherapy in Switzerland [J ] . Ann Oncol , 2020 , 31 ( 4 ): 501 - 506 . DOI: 10.1016/j.annonc.2020.01.007 http://doi.org/10.1016/j.annonc.2020.01.007 https://linkinghub.elsevier.com/retrieve/pii/S0923753420359287 https://linkinghub.elsevier.com/retrieve/pii/S0923753420359287

WANG Y , ZHANG T , HUANG Y L , et al . Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage Ⅲ non-small cell lung cancer: a systematic review and meta-analysis [J ] . Int J Radiat Oncol Biol Phys , 2022 , 112 ( 5 ): 1154 - 1164 . DOI: 10.1016/j.ijrobp.2021.12.150 http://doi.org/10.1016/j.ijrobp.2021.12.150 https://linkinghub.elsevier.com/retrieve/pii/S0360301621034222 https://linkinghub.elsevier.com/retrieve/pii/S0360301621034222

OFFIN M , SHAVERDIAN N , RIMNER A , et al . Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage Ⅲ non-small cell lung cancers treated with chemoradiation and durvalumab [J ] . Radiother Oncol , 2020 , 149 : 205 - 211 . DOI: 10.1016/j.radonc.2020.04.047 http://doi.org/10.1016/j.radonc.2020.04.047 https://linkinghub.elsevier.com/retrieve/pii/S0167814020302280 https://linkinghub.elsevier.com/retrieve/pii/S0167814020302280

SOCINSKI M A , ÖZGÜROĞLU M , VILLEGAS A , et al . Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage Ⅲ non-small cell lung cancer (PACIFIC) [J ] . Clin Lung Cancer , 2021 , 22 ( 6 ): 549 - 561 . DOI: 10.1016/j.cllc.2021.05.009 http://doi.org/10.1016/j.cllc.2021.05.009 https://linkinghub.elsevier.com/retrieve/pii/S1525730421001443 https://linkinghub.elsevier.com/retrieve/pii/S1525730421001443

KEIR M E , FRANCISCO L M , SHARPE A H . PD-1 and its ligands in T-cell immunity [J ] . Curr Opin Immunol , 2007 , 19 ( 3 ): 309 - 314 . DOI: 10.1016/j.coi.2007.04.012 http://doi.org/10.1016/j.coi.2007.04.012 https://linkinghub.elsevier.com/retrieve/pii/S0952791507000647 https://linkinghub.elsevier.com/retrieve/pii/S0952791507000647

KEIR M E , BUTTE M J , FREEMAN G J , et al . PD-1 and its ligands in tolerance and immunity [J ] . Annu Rev Immunol , 2008 , 26 : 677 - 704 . DOI: 10.1146/annurev.immunol.26.021607.090331 http://doi.org/10.1146/annurev.immunol.26.021607.090331 https://www.annualreviews.org/doi/10.1146/annurev.immunol.26.021607.090331 https://www.annualreviews.org/doi/10.1146/annurev.immunol.26.021607.090331

PAZ-ARES L , SPIRA A , RABEN D , et al . Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage Ⅲ non-small cell lung cancer in the PACIFIC trial [J ] . Ann Oncol , 2020 , 31 ( 6 ): 798 - 806 . DOI: 10.1016/j.annonc.2020.03.287 http://doi.org/10.1016/j.annonc.2020.03.287 https://linkinghub.elsevier.com/retrieve/pii/S0923753420363742 https://linkinghub.elsevier.com/retrieve/pii/S0923753420363742

TUFMAN A , NEUMANN J , MANAPOV F , et al . Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase Ⅲ German intergroup lung trial (GILT) [J ] . Lung Cancer , 2021 , 160 : 17 - 27 . DOI: 10.1016/j.lungcan.2021.07.008 http://doi.org/10.1016/j.lungcan.2021.07.008 https://linkinghub.elsevier.com/retrieve/pii/S0169500221004700 https://linkinghub.elsevier.com/retrieve/pii/S0169500221004700

DOVEDI S J , ADLARD A L , LIPOWSKA-BHALLA G , et al . Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade [J ] . Cancer Res , 2014 , 74 ( 19 ): 5458 - 5468 .

AREDO J V , MAMBETSARIEV I , HELLYER J A , et al . Durvalumab for stage & #x02162; EGFR -mutated NSCLC after definitive chemoradiotherapy [J ] . J Thorac Oncol , 2021 , 16 ( 6 ): 1030 - 1041 . DOI: 10.1016/j.jtho.2021.01.1628 http://doi.org/10.1016/j.jtho.2021.01.1628 https://linkinghub.elsevier.com/retrieve/pii/S1556086421017020 https://linkinghub.elsevier.com/retrieve/pii/S1556086421017020

TO K K W , FONG W , CHO W C S . Immunotherapy in treating EGFR -mutant lung cancer: current challenges and new strategies [J ] . Front Oncol , 2021 , 11 : 635007 . DOI: 10.3389/fonc.2021.635007 http://doi.org/10.3389/fonc.2021.635007 https://www.frontiersin.org/articles/10.3389/fonc.2021.635007/full https://www.frontiersin.org/articles/10.3389/fonc.2021.635007/full

BORGHAEI H , PAZ-ARES L , HORN L , et al . Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer [J ] . N Engl J Med , 2015 , 373 ( 17 ): 1627 - 1639 . DOI: 10.1056/NEJMoa1507643 http://doi.org/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643

LEE C K , MAN J , LORD S , et al . Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis [J ] . JAMA Oncol , 2018 , 4 ( 2 ): 210 - 216 . DOI: 10.1001/jamaoncol.2017.4427 http://doi.org/10.1001/jamaoncol.2017.4427 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.4427 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.4427

HELLYER J A , AREDO J V , DAS M , et al . Role of consolidation durvalumab in patients with EGFR - and HER 2-mutant unresectable stage & #x02162; NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 5 ): 868 - 872 . DOI: 10.1016/j.jtho.2020.12.020 http://doi.org/10.1016/j.jtho.2020.12.020 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000447 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000447

XING L G , WU G , WANG L H , et al . Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage Ⅲ epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial [J ] . Int J Radiat Oncol Biol Phys , 2021 , 109 ( 5 ): 1349 - 1358 . DOI: 10.1016/j.ijrobp.2020.11.026 http://doi.org/10.1016/j.ijrobp.2020.11.026 https://linkinghub.elsevier.com/retrieve/pii/S036030162034548X https://linkinghub.elsevier.com/retrieve/pii/S036030162034548X

AKAMATSU H , MURAKAMI H , HARADA H , et al . Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC with EGFR mutation; west Japan oncology group 6911L [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): 1745 - 1752 . DOI: 10.1016/j.jtho.2021.05.019 http://doi.org/10.1016/j.jtho.2021.05.019 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021900 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021900

HOTTA K , SAEKI S , YAMAGUCHI M , et al . Gefitinib induction followed by chemoradiotherapy in EGFR -mutant, locally advanced non-small cell lung cancer: LOGIK0902/OLCSG0905 phase & #x02161; study [J ] . ESMO Open , 2021 , 6 ( 4 ): 100191 . DOI: 10.1016/j.esmoop.2021.100191 http://doi.org/10.1016/j.esmoop.2021.100191 https://linkinghub.elsevier.com/retrieve/pii/S2059702921001526 https://linkinghub.elsevier.com/retrieve/pii/S2059702921001526

DURM G A , JABBOUR S K , ALTHOUSE S K , et al . A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage Ⅲ non-small cell lung cancer : Hoosier Cancer Research Network LUN 14-179[J ] . Cancer , 2020 , 126 ( 19 ): 4353 - 4361 . DOI: 10.1002/cncr.33083 http://doi.org/10.1002/cncr.33083 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33083 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33083

HUNG A , LEE K M , LYNCH J A , et al . Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage Ⅲ non-small cell lung cancer [J ] . BMC Cancer , 2021 , 21 ( 1 ): 824 . DOI: 10.1186/s12885-021-08577-y http://doi.org/10.1186/s12885-021-08577-y https://doi.org/10.1186/s12885-021-08577-y https://doi.org/10.1186/s12885-021-08577-y

ZHANG T , BI N , ZHOU Z M , et al . The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy [J ] . J Thorac Dis , 2020 , 12 ( 8 ): 4347 - 4356 . DOI: 10.21037/jtd-20-2137 http://doi.org/10.21037/jtd-20-2137 http://jtd.amegroups.com/article/view/42685/html http://jtd.amegroups.com/article/view/42685/html

SENAN S , OKAMOTO I , LEE G W , et al . Design and rationale for a phase Ⅲ, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer: the ADRIATIC study [J ] . Clin Lung Cancer , 2020 , 21 ( 2 ): e84-e88.

JAZIEH A R , ONAL H C , TAN D S W , et al . Real-world treatment patterns and clinical outcomes in patients with stage Ⅲ NSCLC: results of KINDLE, a multicountry observational study [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): 1733 - 1744 . DOI: 10.1016/j.jtho.2021.05.003 http://doi.org/10.1016/j.jtho.2021.05.003 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021742 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021742

ZHOU Q , CHEN M , WU G , et al . GEMSTONE-301: a phase Ⅲ clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage Ⅲ) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [J ] . Transl Lung Cancer Res , 2020 , 9 ( 5 ): 2008 - 2015 . DOI: 10.21037/tlcr-20-608 http://doi.org/10.21037/tlcr-20-608 http://tlcr.amegroups.com/article/view/41261/html http://tlcr.amegroups.com/article/view/41261/html

MYERS C J , LU B . Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody correlated with increased T-cell infiltration into cardiac and lung tissues [J ] . Int J Radiat Oncol Biol Phys , 2017 , 99 ( 5 ): 1129 - 1136 . DOI: 10.1016/j.ijrobp.2017.06.2452 http://doi.org/10.1016/j.ijrobp.2017.06.2452 https://linkinghub.elsevier.com/retrieve/pii/S0360301617335186 https://linkinghub.elsevier.com/retrieve/pii/S0360301617335186

DU S S , ZHOU L , ALEXANDER G S , et al . PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes [J ] . J Thorac Oncol , 2018 , 13 ( 4 ): 510 - 520 . DOI: 10.1016/j.jtho.2017.12.002 http://doi.org/10.1016/j.jtho.2017.12.002 https://linkinghub.elsevier.com/retrieve/pii/S1556086417330812 https://linkinghub.elsevier.com/retrieve/pii/S1556086417330812

PETERS S , FELIP E , DAFNI U , et al . Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage Ⅲ non-small cell lung cancer-the ETOP NICOLAS trial [J ] . Lung Cancer , 2019 , 133 : 83 - 87 . DOI: 10.1016/j.lungcan.2019.05.001 http://doi.org/10.1016/j.lungcan.2019.05.001 https://linkinghub.elsevier.com/retrieve/pii/S0169500219304416 https://linkinghub.elsevier.com/retrieve/pii/S0169500219304416

PILLAI R N , BEHERA M , OWONIKOKO T K , et al . Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature [J ] . Cancer , 2018 , 124 ( 2 ): 271 - 277 . DOI: 10.1002/cncr.31043 http://doi.org/10.1002/cncr.31043 https://onlinelibrary.wiley.com/doi/10.1002/cncr.31043 https://onlinelibrary.wiley.com/doi/10.1002/cncr.31043

PETERS S , FELIP E , DAFNI U , et al . Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage ⅢA-B NSCLC: results from the European thoracic oncology platform NICOLAS phase Ⅱ trial (European thoracic oncology platform 6-14) [J ] . J Thorac Oncol , 2021 , 16 ( 2 ): 278 - 288 . DOI: 10.1016/j.jtho.2020.10.129 http://doi.org/10.1016/j.jtho.2020.10.129 https://linkinghub.elsevier.com/retrieve/pii/S1556086420309953 https://linkinghub.elsevier.com/retrieve/pii/S1556086420309953

LIN S H , LIN Y , YAO L Y , et al . Phase Ⅱ trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC [J ] . J Thorac Oncol , 2020 , 15 ( 2 ): 248 - 257 . DOI: 10.1016/j.jtho.2019.10.024 http://doi.org/10.1016/j.jtho.2019.10.024 https://linkinghub.elsevier.com/retrieve/pii/S1556086419336597 https://linkinghub.elsevier.com/retrieve/pii/S1556086419336597

JABBOUR S K , BERMAN A T , DECKER R H , et al. Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial [J ] . JAMA Oncol , 2020 , 6 ( 6 ): 848 - 855 . DOI: 10.1001/jamaoncol.2019.6731 http://doi.org/10.1001/jamaoncol.2019.6731 https://jamanetwork.com/journals/jamaoncology/fullarticle/2761665 https://jamanetwork.com/journals/jamaoncology/fullarticle/2761665

JABBOUR S K , LEE K H , FROST N , et al . Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage Ⅲ non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial [J ] . JAMA Oncol , 2021 , 7 ( 9 ): 1 - 9 .

LEE Y J , AUH S L , WANG Y G , et al . Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: changing strategies for cancer treatment [J ] . Blood , 2009 , 114 ( 3 ): 589 - 595 .

GOUGH M J , CRITTENDEN M R , SARFF M , et al . Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice [J ] . J Immunother , 2010 , 33 ( 8 ): 798 - 809 . DOI: 10.1097/CJI.0b013e3181ee7095 http://doi.org/10.1097/CJI.0b013e3181ee7095 https://journals.lww.com/00002371-201010000-00006 https://journals.lww.com/00002371-201010000-00006

DEMARIA S , KAWASHIMA N , YANG A M , et al . Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer [J ] . Clin Cancer Res , 2005 , 11 ( 2 Pt 1 ): 728 - 734 . DOI: 10.1158/1078-0432.728.11.2 http://doi.org/10.1158/1078-0432.728.11.2 https://aacrjournals.org/clincancerres/article/11/2/728/186831/Immune-Mediated-Inhibition-of-Metastases-after https://aacrjournals.org/clincancerres/article/11/2/728/186831/Immune-Mediated-Inhibition-of-Metastases-after

FORDE P M , CHAFT J E , SMITH K N , et al . Neoadjuvant PD-1 blockade in resectable lung cancer [J ] . N Engl J Med , 2018 , 378 ( 21 ): 1976 - 1986 . DOI: 10.1056/NEJMoa1716078 http://doi.org/10.1056/NEJMoa1716078 http://www.nejm.org/doi/10.1056/NEJMoa1716078 http://www.nejm.org/doi/10.1056/NEJMoa1716078

YOST K E , SATPATHY A T , WELLS D K , et al . Clonal replacement of tumor-specific T cells following PD-1 blockade [J ] . Nat Med , 2019 , 25 ( 8 ): 1251 - 1259 . DOI: 10.1038/s41591-019-0522-3 http://doi.org/10.1038/s41591-019-0522-3 https://doi.org/10.1038/s41591-019-0522-3 https://doi.org/10.1038/s41591-019-0522-3

KATO R , HAYASHI H , CHIBA Y , et al . Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L) [J ] . J Immunother Cancer , 2020 , 8 ( 1 ): e000350.

SCHVARTSMAN G , PENG S A , BIS G , et al . Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer [J ] . Lung Cancer , 2017 , 112 : 90 - 95 . DOI: 10.1016/j.lungcan.2017.07.034 http://doi.org/10.1016/j.lungcan.2017.07.034 https://linkinghub.elsevier.com/retrieve/pii/S0169500217304336 https://linkinghub.elsevier.com/retrieve/pii/S0169500217304336

ROSS H J , KOZONO D E , URBANIC J J , et al . AFT-16: Phase Ⅱ trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage Ⅲ non-small cell lung cancer (NSCLC) [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 8513 . DOI: 10.1200/JCO.2021.39.15_suppl.8513 http://doi.org/10.1200/JCO.2021.39.15_suppl.8513 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8513 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8513

BRAHMER J R . Harnessing the immune system for the treatment of non-small cell lung cancer [J ] . J Clin Oncol , 2013 , 31 ( 8 ): 1021 - 1028 . DOI: 10.1200/JCO.2012.45.8703 http://doi.org/10.1200/JCO.2012.45.8703 https://ascopubs.org/doi/10.1200/JCO.2012.45.8703 https://ascopubs.org/doi/10.1200/JCO.2012.45.8703

SWANN J B , SMYTH M J . Immune surveillance of tumors [J ] . J Clin Invest , 2007 , 117 ( 5 ): 1137 - 1146 . DOI: 10.1172/JCI31405 http://doi.org/10.1172/JCI31405 http://www.jci.org/cgi/doi/10.1172/JCI31405 http://www.jci.org/cgi/doi/10.1172/JCI31405

APETOH L , GHIRINGHELLI F , TESNIERE A , et al . Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J ] . Nat Med , 2007 , 13 ( 9 ): 1050 - 1059 . DOI: 10.1038/nm1622 http://doi.org/10.1038/nm1622 http://www.nature.com/articles/nm1622 http://www.nature.com/articles/nm1622

FORMENTI S C , DEMARIA S . Combining radiotherapy and cancer immunotherapy: a paradigm shift [J ] . J Natl Cancer Inst , 2013 , 105 ( 4 ): 256 - 265 . DOI: 10.1093/jnci/djs629 http://doi.org/10.1093/jnci/djs629 https://academic.oup.com/jnci/article/105/4/256/926146 https://academic.oup.com/jnci/article/105/4/256/926146

LADBURY C J , RUSTHOVEN C G , CAMIDGE D R , et al . Impact of radiation dose to the host immune system on tumor control and survival for stage Ⅲ non-small cell lung cancer treated with definitive radiation therapy [J ] . Int J Radiat Oncol Biol Phys , 2019 , 105 ( 2 ): 346 - 355 . DOI: 10.1016/j.ijrobp.2019.05.064 http://doi.org/10.1016/j.ijrobp.2019.05.064 https://linkinghub.elsevier.com/retrieve/pii/S0360301619308181 https://linkinghub.elsevier.com/retrieve/pii/S0360301619308181

MATTES M D , EUBANK T D , ALMUBARAK M , et al . A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer [J ] . Clin Lung Cancer , 2021 , 22 ( 4 ): 268 - 273 . DOI: 10.1016/j.cllc.2021.01.012 http://doi.org/10.1016/j.cllc.2021.01.012 https://linkinghub.elsevier.com/retrieve/pii/S1525730421000152 https://linkinghub.elsevier.com/retrieve/pii/S1525730421000152

VENKATESULU B P , MALLICK S , LIN S H , et al . A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors [J ] . Crit Rev Oncol Hematol , 2018 , 123 : 42 - 51 . DOI: 10.1016/j.critrevonc.2018.01.003 http://doi.org/10.1016/j.critrevonc.2018.01.003 https://linkinghub.elsevier.com/retrieve/pii/S1040842817303499 https://linkinghub.elsevier.com/retrieve/pii/S1040842817303499

TANG C , LIAO Z X , GOMEZ D , et al . Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes [J ] . Int J Radiat Oncol Biol Phys , 2014 , 89 ( 5 ): 1084 - 1091 . DOI: 10.1016/j.ijrobp.2014.04.025 http://doi.org/10.1016/j.ijrobp.2014.04.025 https://linkinghub.elsevier.com/retrieve/pii/S0360301614004969 https://linkinghub.elsevier.com/retrieve/pii/S0360301614004969

CAMPIAN J L , YE X B , BROCK M , et al . Treatment-related lymphopenia in patients with stage Ⅲ non-small cell lung cancer [J ] . Cancer Invest , 2013 , 31 ( 3 ): 183 - 188 . DOI: 10.3109/07357907.2013.767342 http://doi.org/10.3109/07357907.2013.767342 http://www.tandfonline.com/doi/full/10.3109/07357907.2013.767342 http://www.tandfonline.com/doi/full/10.3109/07357907.2013.767342

CHO O , OH Y T , CHUN M , et al . Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer [J ] . Tumour Biol , 2016 , 37 ( 1 ): 971 - 978 . DOI: 10.1007/s13277-015-3888-y http://doi.org/10.1007/s13277-015-3888-y http://link.springer.com/10.1007/s13277-015-3888-y http://link.springer.com/10.1007/s13277-015-3888-y

FARHOOD B , NAJAFI M , MORTEZAEE K . CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review [J ] . J Cell Physiol , 2019 , 234 ( 6 ): 8509 - 8521 . DOI: 10.1002/jcp.27782 http://doi.org/10.1002/jcp.27782 https://onlinelibrary.wiley.com/doi/10.1002/jcp.27782 https://onlinelibrary.wiley.com/doi/10.1002/jcp.27782

BÖTTCHER J P , SOUSA C R E . The role of type 1 conventional dendritic cells in cancer immunity [J ] . Trends Cancer , 2018 , 4 ( 11 ): 784 - 792 . DOI: 10.1016/j.trecan.2018.09.001 http://doi.org/10.1016/j.trecan.2018.09.001 https://linkinghub.elsevier.com/retrieve/pii/S2405803318301948 https://linkinghub.elsevier.com/retrieve/pii/S2405803318301948

ABRAVAN A , FAIVRE-FINN C , KENNEDY J , et al . Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer [J ] . J Thorac Oncol , 2020 , 15 ( 10 ): 1624 - 1635 . DOI: 10.1016/j.jtho.2020.06.008 http://doi.org/10.1016/j.jtho.2020.06.008 https://linkinghub.elsevier.com/retrieve/pii/S1556086420304780 https://linkinghub.elsevier.com/retrieve/pii/S1556086420304780

LI R J , YU L , LIN S X , et al . Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF) [J ] . Radiat Oncol , 2016 , 11 ( 1 ): 124 . DOI: 10.1186/s13014-016-0698-3 http://doi.org/10.1186/s13014-016-0698-3 http://ro-journal.biomedcentral.com/articles/10.1186/s13014-016-0698-3 http://ro-journal.biomedcentral.com/articles/10.1186/s13014-016-0698-3

CHEN M , BAO Y , MA H L , et al . Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study [J ] . Biomed Res Int , 2013 , 2013 : 371819 .

SENAN S , BURGERS S , SAMSON M J , et al . Can elective nodal irradiation be omitted in stage Ⅲ non-small cell lung cancer? Analysis of recurrences in a phase Ⅱ study of induction chemotherapy and involved-field radiotherapy [J ] . Int J Radiat Oncol Biol Phys , 2002 , 54 ( 4 ): 999 - 1006 . DOI: 10.1016/S0360-3016(02)03028-6 http://doi.org/10.1016/S0360-3016(02)03028-6 https://linkinghub.elsevier.com/retrieve/pii/S0360301602030286 https://linkinghub.elsevier.com/retrieve/pii/S0360301602030286

ROSENZWEIG K E , SURA S , JACKSON A , et al . Involved-field radiation therapy for inoperable non-small cell lung cancer [J ] . J Clin Oncol , 2007 , 25 ( 35 ): 5557 - 5561 . DOI: 10.1200/JCO.2007.13.2191 http://doi.org/10.1200/JCO.2007.13.2191 https://ascopubs.org/doi/10.1200/JCO.2007.13.2191 https://ascopubs.org/doi/10.1200/JCO.2007.13.2191

FERNANDES A T , SHEN J , FINLAY J , et al . Elective nodal irradiation (ENI) vs involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes [J ] . Radiother Oncol , 2010 , 95 ( 2 ): 178 - 184 . DOI: 10.1016/j.radonc.2010.02.007 http://doi.org/10.1016/j.radonc.2010.02.007 https://linkinghub.elsevier.com/retrieve/pii/S0167814010000848 https://linkinghub.elsevier.com/retrieve/pii/S0167814010000848

YUAN S H , SUN X D , LI M H , et al . A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage Ⅲ nonsmall cell lung cancer [J ] . Am J Clin Oncol , 2007 , 30 ( 3 ): 239 - 244 . DOI: 10.1097/01.coc.0000256691.27796.24 http://doi.org/10.1097/01.coc.0000256691.27796.24 https://journals.lww.com/00000421-200706000-00005 https://journals.lww.com/00000421-200706000-00005

TOPKAN E , OZDEMIR Y , GULER O C , et al . Comparison of involved field radiotherapy versus elective nodal irradiation in stage ⅢB/C non-small cell lung carcinoma patients treated with concurrent chemoradiotherapy: a propensity score matching study [J ] . J Oncol , 2020 , 2020 : 7083149.

WITHERS H R , PETERS L J , TAYLOR J M G . Dose-response relationship for radiation therapy of subclinical disease [J ] . Int J Radiat Oncol , 1995 , 31 ( 2 ): 353 - 359 . DOI: 10.1016/0360-3016(94)00354-N http://doi.org/10.1016/0360-3016(94)00354-N https://linkinghub.elsevier.com/retrieve/pii/036030169400354N https://linkinghub.elsevier.com/retrieve/pii/036030169400354N

WITHERS H R , SUWINSKI R . Radiation dose response for subclinical metastases [J ] . Semin Radiat Oncol , 1998 , 8 ( 3 ): 224 - 228 . DOI: 10.1016/S1053-4296(98)80048-9 http://doi.org/10.1016/S1053-4296(98)80048-9 https://linkinghub.elsevier.com/retrieve/pii/S1053429698800489 https://linkinghub.elsevier.com/retrieve/pii/S1053429698800489

XIA F , ZHOU L J , YANG X , et al . Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? A dosimetric evaluation of three different treatment plans [J ] . J Thorac Dis , 2017 , 9 ( 12 ): 5194 - 5202 . DOI: 10.21037/jtd.2017.10.147 http://doi.org/10.21037/jtd.2017.10.147 http://jtd.amegroups.com/article/view/17167/14315 http://jtd.amegroups.com/article/view/17167/14315

ZOU L Q , CHU L , XIA F , et al . Is clinical target volume necessary? A failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique [J ] . Transl Lung Cancer Res , 2020 , 9 ( 5 ): 1986 - 1995 . DOI: 10.21037/tlcr-20-523 http://doi.org/10.21037/tlcr-20-523 http://tlcr.amegroups.com/article/view/42241/html http://tlcr.amegroups.com/article/view/42241/html

LIANG X C , YU H M , YU R , et al . Efficacy of the smaller target volume for stage Ⅲ non-small cell lung cancer treated with intensity-modulated radiotherapy [J ] . Mol Clin Oncol , 2015 , 3 ( 5 ): 1172 - 1176 . DOI: 10.3892/mco.2015.588 http://doi.org/10.3892/mco.2015.588 https://www.spandidos-publications.com/10.3892/mco.2015.588 https://www.spandidos-publications.com/10.3892/mco.2015.588

KILBURN J M , LUCAS J T , SOIKE M H , et al . Is a clinical target volume (CTV) necessary in the treatment of lung cancer in the modern era combining 4-D imaging and image-guided radiotherapy (IGRT)? [J ] . Cureus , 2016 , 8 ( 1 ): e466.

JIANG C X , HAN S Y , CHEN W C , et al . A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage Ⅲ non-small cell lung cancer [J ] . Oncotarget , 2018 , 9 ( 15 ): 12443 - 12451 . DOI: 10.18632/oncotarget.23849 http://doi.org/10.18632/oncotarget.23849 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23849 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23849

MORISADA M , CLAVIJO P E , MOORE E , et al . PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation [J ] . Oncoimmunology , 2017 , 7 ( 3 ): e1395996.

ZHANG T , YU H F , NI C , et al . Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage Ⅰ non-small cell lung cancer [J ] . Sci Rep , 2017 , 7 ( 1 ): 4866 . DOI: 10.1038/s41598-017-04978-x http://doi.org/10.1038/s41598-017-04978-x http://www.nature.com/articles/s41598-017-04978-x http://www.nature.com/articles/s41598-017-04978-x

PAVLOPOULOU A , BAGOS P G , KOUTSANDREA V , et al . Molecular determinants of radiosensitivity in normal and tumor tissue: a bioinformatic approach [J ] . Cancer Lett , 2017 , 403 : 37 - 47 . DOI: 10.1016/j.canlet.2017.05.023 http://doi.org/10.1016/j.canlet.2017.05.023 https://linkinghub.elsevier.com/retrieve/pii/S0304383517303695 https://linkinghub.elsevier.com/retrieve/pii/S0304383517303695

KERNS S L , FACHAL L , DORLING L , et al . Radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy [J ] . J Natl Cancer Inst , 2020 , 112 ( 2 ): 179 - 190 . DOI: 10.1093/jnci/djz075 http://doi.org/10.1093/jnci/djz075 https://academic.oup.com/jnci/article/112/2/179/5490201 https://academic.oup.com/jnci/article/112/2/179/5490201

BERNICHON E , VALLARD A , WANG Q , et al . Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol [J ] . Ann Oncol , 2017 , 28 ( 11 ): 2773 - 2779 . DOI: 10.1093/annonc/mdx488 http://doi.org/10.1093/annonc/mdx488 https://linkinghub.elsevier.com/retrieve/pii/S0923753419346071 https://linkinghub.elsevier.com/retrieve/pii/S0923753419346071

AHMED K A , BERGLUND A E , WELSH E A , et al . The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity [J ] . Neuro Oncol , 2017 , 19 ( 8 ): 1145 - 1146 . DOI: 10.1093/neuonc/nox043 http://doi.org/10.1093/neuonc/nox043 https://academic.oup.com/neuro-oncology/article/19/8/1145/3096451 https://academic.oup.com/neuro-oncology/article/19/8/1145/3096451

JIN J Y , WANG W L , TEN HAKEN R K , et al . Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer [J ] . Radiother Oncol , 2015 , 117 ( 1 ): 77 - 82 . DOI: 10.1016/j.radonc.2015.07.024 http://doi.org/10.1016/j.radonc.2015.07.024 https://linkinghub.elsevier.com/retrieve/pii/S0167814015003783 https://linkinghub.elsevier.com/retrieve/pii/S0167814015003783

LEE Y S , OH J H , YOON S , et al . Differential gene expression profiles of radioresistant non-small cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation [J ] . Int J Radiat Oncol Biol Phys , 2010 , 77 ( 3 ): 858 - 866 . DOI: 10.1016/j.ijrobp.2009.12.076 http://doi.org/10.1016/j.ijrobp.2009.12.076 https://linkinghub.elsevier.com/retrieve/pii/S036030161000129X https://linkinghub.elsevier.com/retrieve/pii/S036030161000129X

EDVARDSEN H , TEFRE T , JANSEN L , et al . Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence [J ] . Radiat Oncol , 2007 , 2 : 25 . DOI: 10.1186/1748-717X-2-25 http://doi.org/10.1186/1748-717X-2-25 https://doi.org/10.1186/1748-717X-2-25 https://doi.org/10.1186/1748-717X-2-25

SAK A , STUEBEN G , GRONEBERG M , et al . Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines [J ] . Br J Cancer , 2005 , 92 ( 6 ): 1089 - 1097 . DOI: 10.1038/sj.bjc.6602457 http://doi.org/10.1038/sj.bjc.6602457 https://doi.org/10.1038/sj.bjc.6602457 https://doi.org/10.1038/sj.bjc.6602457

SITTHIDEATPHAIBOON P , GALAN-COBO A , NEGRAO M V , et al . STK11/LKB1 mutations in NSCLC are associated with KEAP1/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition [J ] . Clin Cancer Res , 2021 , 27 ( 6 ): 1720 - 1733 . DOI: 10.1158/1078-0432.CCR-20-2859 http://doi.org/10.1158/1078-0432.CCR-20-2859 https://aacrjournals.org/clincancerres/article/27/6/1720/671868/STK11-LKB1-Mutations-in-NSCLC-Are-Associated-with https://aacrjournals.org/clincancerres/article/27/6/1720/671868/STK11-LKB1-Mutations-in-NSCLC-Are-Associated-with

ESCHRICH S A , PRAMANA J , ZHANG H L , et al . A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation [J ] . Int J Radiat Oncol Biol Phys , 2009 , 75 ( 2 ): 489 - 496 . DOI: 10.1016/j.ijrobp.2009.06.014 http://doi.org/10.1016/j.ijrobp.2009.06.014 https://linkinghub.elsevier.com/retrieve/pii/S0360301609009195 https://linkinghub.elsevier.com/retrieve/pii/S0360301609009195

ESCHRICH S , ZHANG H L , ZHAO H Y , et al . Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform [J ] . Int J Radiat Oncol Biol Phys , 2009 , 75 ( 2 ): 497 - 505 . DOI: 10.1016/j.ijrobp.2009.05.056 http://doi.org/10.1016/j.ijrobp.2009.05.056 https://linkinghub.elsevier.com/retrieve/pii/S036030160900830X https://linkinghub.elsevier.com/retrieve/pii/S036030160900830X

TORRES-ROCA J F , ESCHRICH S , ZHAO H Y , et al . Prediction of radiation sensitivity using a gene expression classifier [J ] . Cancer Res , 2005 , 65 ( 16 ): 7169 - 7176 . DOI: 10.1158/0008-5472.CAN-05-0656 http://doi.org/10.1158/0008-5472.CAN-05-0656 https://aacrjournals.org/cancerres/article/65/16/7169/518226/Prediction-of-Radiation-Sensitivity-Using-a-Gene https://aacrjournals.org/cancerres/article/65/16/7169/518226/Prediction-of-Radiation-Sensitivity-Using-a-Gene

SCOTT J G , BERGLUND A , SCHELL M J , et al . A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study [J ] . Lancet Oncol , 2017 , 18 ( 2 ): 202 - 211 . DOI: 10.1016/S1470-2045(16)30648-9 http://doi.org/10.1016/S1470-2045(16)30648-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204516306489 https://linkinghub.elsevier.com/retrieve/pii/S1470204516306489

AHMED K A , LIVERINGHOUSE C L , MILLS M N , et al . Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management [J ] . EBioMedicine , 2019 , 47 : 163 - 169 . DOI: 10.1016/j.ebiom.2019.08.019 http://doi.org/10.1016/j.ebiom.2019.08.019 https://linkinghub.elsevier.com/retrieve/pii/S2352396419305377 https://linkinghub.elsevier.com/retrieve/pii/S2352396419305377

OLIVER D E , MOHAMMADI H , FIGURA N , et al . Novel genomic-based strategies to personalize lymph node radiation therapy [J ] . Semin Radiat Oncol , 2019 , 29 ( 2 ): 111 - 125 . DOI: 10.1016/j.semradonc.2018.11.003 http://doi.org/10.1016/j.semradonc.2018.11.003 https://linkinghub.elsevier.com/retrieve/pii/S1053429618300997 https://linkinghub.elsevier.com/retrieve/pii/S1053429618300997

SCOTT J G , SEDOR G , ELLSWORTH P , et al . Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis [J ] . Lancet Oncol , 2021 , 22 ( 9 ): 1221 - 1229 . DOI: 10.1016/S1470-2045(21)00347-8 http://doi.org/10.1016/S1470-2045(21)00347-8 https://linkinghub.elsevier.com/retrieve/pii/S1470204521003478 https://linkinghub.elsevier.com/retrieve/pii/S1470204521003478

SCOTT J G , SEDOR G , SCARBOROUGH J A , et al . Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 3 ): 428 - 438 . DOI: 10.1016/j.jtho.2020.11.008 http://doi.org/10.1016/j.jtho.2020.11.008 https://linkinghub.elsevier.com/retrieve/pii/S1556086420310467 https://linkinghub.elsevier.com/retrieve/pii/S1556086420310467

NICHOLS R C , HUH S N , HENDERSON R H , et al . Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage Ⅲ non-small cell lung cancer: a dosimetric study [J ] . Clin Lung Cancer , 2011 , 12 ( 4 ): 252 - 257 . DOI: 10.1016/j.cllc.2011.03.027 http://doi.org/10.1016/j.cllc.2011.03.027 https://linkinghub.elsevier.com/retrieve/pii/S1525730411000283 https://linkinghub.elsevier.com/retrieve/pii/S1525730411000283

HIGGINS K A , O'CONNELL K , LIU Y , et al . National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer [J ] . Int J Radiat Oncol Biol Phys , 2017 , 97 ( 1 ): 128 - 137 . DOI: 10.1016/j.ijrobp.2016.10.001 http://doi.org/10.1016/j.ijrobp.2016.10.001 https://linkinghub.elsevier.com/retrieve/pii/S0360301616332758 https://linkinghub.elsevier.com/retrieve/pii/S0360301616332758

GJYSHI O , XU T , ELHAMMALI A , et al . Toxicity and survival after intensity-modulated proton therapy versus passive scattering proton therapy for NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 2 ): 269 - 277 . DOI: 10.1016/j.jtho.2020.10.013 http://doi.org/10.1016/j.jtho.2020.10.013 https://linkinghub.elsevier.com/retrieve/pii/S155608642030839X https://linkinghub.elsevier.com/retrieve/pii/S155608642030839X

LIAO Z X , LEE J J , KOMAKI R , et al . Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small cell lung cancer [J ] . J Clin Oncol , 2018 , 36 ( 18 ): 1813 - 1822 . DOI: 10.1200/JCO.2017.74.0720 http://doi.org/10.1200/JCO.2017.74.0720 https://ascopubs.org/doi/10.1200/JCO.2017.74.0720 https://ascopubs.org/doi/10.1200/JCO.2017.74.0720

TAKAHASHI W , NAKAJIMA M , YAMAMOTO N , et al . A prospective nonrandomized phase Ⅰ/Ⅱ study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC) [J ] . Cancer , 2015 , 121 ( 8 ): 1321 - 1327 . DOI: 10.1002/cncr.29195 http://doi.org/10.1002/cncr.29195 https://onlinelibrary.wiley.com/doi/10.1002/cncr.29195 https://onlinelibrary.wiley.com/doi/10.1002/cncr.29195

ONISHI M , OKONOGI N , OIKE T , et al . High linear energy transfer carbon-ion irradiation increases the release of the immune mediator high mobility group box 1 from human cancer cells [J ] . J Radiat Res , 2018 , 59 ( 5 ): 541 - 546 . DOI: 10.1093/jrr/rry049 http://doi.org/10.1093/jrr/rry049 https://academic.oup.com/jrr/article/59/5/541/5045655 https://academic.oup.com/jrr/article/59/5/541/5045655

ANDO K , FUJITA H , HOSOI A , et al . Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation [J ] . J Radiat Res , 2017 , 58 ( 4 ): 446 - 455 . DOI: 10.1093/jrr/rrx005 http://doi.org/10.1093/jrr/rrx005 https://academic.oup.com/jrr/article/58/4/446/3055267 https://academic.oup.com/jrr/article/58/4/446/3055267

BROWNSTEIN J M , WISDOM A J , CASTLE K D , et al . Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma [J ] . Mol Cancer Ther , 2018 , 17 ( 4 ): 858 - 868 . DOI: 10.1158/1535-7163.MCT-17-0965 http://doi.org/10.1158/1535-7163.MCT-17-0965 https://aacrjournals.org/mct/article/17/4/858/92417/Characterizing-the-Potency-and-Impact-of-Carbon https://aacrjournals.org/mct/article/17/4/858/92417/Characterizing-the-Potency-and-Impact-of-Carbon

Views

5402

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Important clinical research progress in lung cancer in 2022

Current status and future directions of immunotherapy for advanced non-small cell lung cancer

Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

Related Author

Chunxia SU

Caicun ZHOU

Chunxia SU

Caicun ZHOU

梁晓华

黄若凡

詹　琼

LIU Miao

Related Institution

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

复旦大学附属华山医院肿瘤科

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

AI问答

⁰